Trial Profile
A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Lusutrombopag (Primary)
- Indications Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Acronyms L-PLUS 2
- Sponsors Shionogi
- 30 Jun 2023 According to a Shionogi media release, the Mulpleta (Lusutrombopag), has received approval from the Center for Drug Evaluation, NMPA for treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
- 29 Jul 2022 Results of a pooled analysis (JapicCTI-163289, NCT02389621 and JapicCTI-163432 studies) assessing the pharmacokinetics, efficacy, and safety of lusutrombopag in patients with Child-Pugh class C chronic liver disease published in the Advances in Therapy
- 19 May 2020 Results of post hoc analysis assessing the efficacy and safety of lusutrombopag in patients undergoing a GI procedure published in Gastroenterology in conjunction with Digestive Disease Week 2020